beeldscherm schreef op 2 juni 2018 12:07:
'Beautiful blood': How CSL became a global success story
www.smh.com.au/business/markets/beaut...zijn ook met "onderzoek" bezig waar Pharming denk ik 21 june ook iets over zal zeggen..
..een paar zinsnedes,..
the global haemophilia market is worth about $US10.5 billion and is expected to reach $US15.1 billion by 2025.
..csl-112 If the trials prove successful, the scale of future growth is huge.
Cardiovascular disease is the leading cause of death globally. In Australia, an estimated 54,000 people are hospitalised every year as a result of a heart attack.
Numbers of people suffering heart attacks in the United States are about 750,000 every year.
Nearly one in five survivors of heart attack will experience a recurrent event within one year of the initial event. The majority of these recurrent events happen within the first 90 days and are associated with a high rate of morbidity and mortality.
CSL is hoping that its CSL-112 therapy can help prevent repeat heart attacks by removing cholesterol from plaque following a heart attack and stabilising dangerous plaque lesions in the arteries that could otherwise erupt and cause another cardiovascular event.
“Nothing has been able to prevent second heart attacks or stroke within the first 90 days post-heart attack
ze zitten in op het verlagen vh cholesterol